DoP asks NPPA to review, verify Bharat Serum and Vaccine's
The Department of Pharmaceuticals (DoP) has issued an order disposing the review application of Bharat Serum and Vaccine (BSVL) to the National Pharmaceutical Pricing Authority (NPPA) instructing to verify the applicability of GST factor by cross-checking the documents submitted by BSVL pertaining to the formulation Human Normal Immunoglobulin.
DoP asks NPPA to reconsider retail price fixation on Abbott’s
The DoP took up the matter and examined the argument from both the sides, before arriving at a decision to remand the review petition to the NPPA. Abbott, in its review application said that the NPPA fixed the retail price for the formulation based on recommendations of the Multi Disciplinary Committee (MDC) of Experts, using the average of
After govt move to review remdesivir MRP, pharma firms say
Price varies between Rs 899-Rs 5,400 per vial Zydus Cadila’s brand Remdac is the cheapest generic version of Gilead Sciences’ injectable repurposed drug remdesivir which was launched in August last year at a price of Rs 2,800 per vial. It has now been reduced further to Rs 899.
Govt asks NPPA to re-fix ceiling prices of three essential
The NPPA had set the ceiling price at Rs 2.59 per tablet on June 2. Consequently, on October 6, the DoP directed the NPPA to examine all the relevant data/information furnished by the Abbott Healthcare “again on merits and to re-fix the ceiling price of Propanolol 40mg tablets within one month”.
DoP asks NPPA to review prices fixed for Eli Lilly’s insulin
However, the NPPA asked the company to stick to the insulin ceiling price it had fixed earlier, after the review of the case. Eli Lilly has challenged fixing the prices in respect of five different imported formulations of injection Insulin Lispro (Humalog) through an order dated July 19, 2012.
